Search

Displaying results 3731 - 3740 of 10000 in total
  1. Drug

    GR270773

    go.drugbank.com/drugs/DB06427
    Investigational

    NCT00089986 (completed with results, treatment of suspected or confirmed gram-negative severe sepsis in adults, comparing GR270773 with a placebo). … GR270773, was investigated in two clinical trials for its potential to treat sepsis: NCT00158769 (completed, comparing the effects of infusion between healthy adults and those with damaged livers) and

  2. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  3. Drug

    Milveterol

    go.drugbank.com/drugs/DB05043
    Investigational

    GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.

  4. Drug

    Gacyclidine

    go.drugbank.com/drugs/DB13096
    Investigational

    Gacyclidine has been used in trials studying the treatment of Tinnitus.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  6. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. … Laquinimod is an immunomodulator developed by Active Biotech and produced by Teva Pharmaceutical Industries.

  7. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … [L11100] Clinical trials are expected to begin in 2020.[L11103,L11100]

  8. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in

  9. Drug

    99mTc-14 F7 Mab

    go.drugbank.com/drugs/DB05867
    Experimental

    99mTc 14F7 Mab has strong anti tumor activity against myeloma cells in vivo.

  10. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.